BOCA RATON, Fla., October 28, 2015—RxStrategies, Inc. (www.rxstrategies.com) is pleased to announce the appointment of Skip Devanny to the position of Chief Revenue Officer. In this new role, Skip joins the RxStrategies’ senior leadership team and has responsibility for sales and marketing including the delivery of customized 340B pharmacy administration and split billing solutions to the growing 340B marketplace.
“I am very pleased to welcome Skip to the RxStrategies’ leadership team,” said Fenton Markevich, Chief Executive Officer for RxStrategies. “We look forward to incorporating Skip’s deep 340B market knowledge, split billing and contract pharmacy product expertise for the benefit of our existing and future clients. We believe that Skip will provide unique product and market insights and leadership to the strong team RxStrategies has in place today. In particular, he will help RxStrategies highlight and promote our enhanced 340B CompliancePlus product and its unique and customer-centric split billing solutions.”
Skip joins RxStrategies with acknowledged industry leadership and an extensive background in both split billing and contract pharmacy market facing roles within the 340B space. Skip is a graduate of Trinity University and is finalizing his master’s degree in business administration at Washington University in St. Louis.
“RxStrategies has a strong reputation in the marketplace with both a unique and transparent processing solution, and a proprietary split billing solution and service model to address this complex market,” said Devanny. “I am excited to join and help deliver solutions for this growing industry leader. My career has been spent using a consultative approach and I look forward to continuing that tradition by providing 340B guidance and insight to our current and future clients.”